Aratana Therapeutics Announces Results from AT-001 Study in Client-Owned Dogs with Osteoarthritis

Aratana Therapeutics (NASDAQ: PETX ) today announced positive results from its dose-ranging study of AT-001, the company's innovative drug for treating pain in dogs with osteoarthritis. In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo (p